In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Conjugate Efpeglenatide | Synthetic analog Semaglutide | |
|---|---|---|---|
| Identity | |||
| Kind | Conjugate | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 91 | 4,624 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 17 (17 in people) | 1,224 (1,221 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 2 | 663 · 284 active124 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Efpeglenatide | Semaglutide |
|---|---|---|
| Body weightMetabolic and weight | 1111 | 969954105 |
| Adverse events |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Ozempic says: “Adjunct to diet and exercise for glycemic control in adults with type 2 diabetes; reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; reduce the risk of sustained eGFR decline…”
66 |
7757723 |
| Glycemic controlMetabolic and weight | 2525 | 66866512 |
|---|
| Gastrointestinal adverse eventsGastrointestinal | 1010 | 345345 |
|---|
| Cardiovascular eventsCardiovascular | 1919 | 2672634 |
|---|
| Kidney functionKidney and urinary | 66 | 1361351 |
|---|
| LipidsMetabolic and weight | 22 | 1181171 |
|---|
| PharmacokineticsPharmacology | 99 | 93894 |
|---|
| Gastrointestinal motilityGastrointestinal | 22 | 15132 |
|---|
| Immune responseImmune and inflammation | 11 | 44 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Semaglutide differs from Glucagon-like peptide 1 (7-37) at 2 positions and carries 1 added group.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
2 trials · 1 completed · source ClinicalTrials.gov (opens in a new tab)
Hanmi Pharmaceutical Company Limited209 participantsFeb 2014 to Apr 2015
Type 2 Diabetes
Hanmi Pharmaceutical Company Limited44 participantsDec 2013 to est. Dec 2014
Diabetes Mellitus
Top 3 of 663 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S17,604 participants24 Oct 2018 to 29 Jun 2023
Overweight · Obesity
Novo Nordisk A/S9,651 participants17 Jun 2019 to 23 Aug 2024
Diabetes Mellitus, Type 2
Novo Nordisk A/S3,533 participants17 Jun 2019 to 9 Jan 2024
Diabetes Mellitus, Type 2
124 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Efpeglenatide | Semaglutide |
|---|---|---|
| Kidney functionKidney and urinaryCompared as: share of people in the arm that got the peptide, in % | 13% Participants with composite renal outcome Placebo: 18.4% Dose studied: 4 or 6 mg weeklymedian follow-up 1.81 yearsn = 4,0762021 | 1.8% Incidence Placebo: 2.2% Dose studied: 2.4 mg once weeklyn = 17,6042024 |
| Body weightMetabolic and weightCompared as: difference from placebo, in kg | 5.6 to 7.3 kg Weight reduction Dose studied: 4 mg or 6 mg once weekly, 6 mg or 8 mg once every 2 weeks20 weeksn not reported2022 | −9.1 kg |
| Glycemic controlMetabolic and weightCompared as: difference from placebo, in % | 0.3 to 0.38% HbA1c reduction Dose studied: 4 mg or 6 mg once weekly, 6 mg or 8 mg once every 2 weeks20 weeksn not reported2022 | −1.6 to −0.4% |
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | 5 to 19% Discontinuation due to adverse events Dose studied: 4 mg once weekly, 6 mg once weekly, 6 mg once every 2 wk, or 8 mg once every 2 wk20 weeksn not reported2019 |
13%
Participants with composite renal outcome
Placebo: 18.4%
Dose studied: 4 or 6 mg weeklymedian follow-up 1.81 yearsn = 4,0762021
1.8%
Incidence
Placebo: 2.2%
Dose studied: 2.4 mg once weeklyn = 17,6042024
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Efpeglenatide | Semaglutide |
|---|---|---|
| Cardiovascular eventsCardiovascularCompared as: value in the arm that got the peptide, in % | No comparable result 10 randomized-trial results measure it in another way or another unit. | 6.5% primary end-point event rate Placebo: 8% Dose studied: 2.4 mg once weeklyn = 17,604 |
Total body weight change
Dose studied: 2.4 mg/wk24 weeksn = 1012026
Estimated treatment difference
Dose studied: 2.5-40 mg once daily26 weeksn not reported2017
16.6%
discontinuation due to adverse events
Placebo: 8.2%
Dose studied: 2.4 mg once weeklyn = 17,6042023
5.6 to 7.3 kg
Weight reduction
Dose studied: 4 mg or 6 mg once weekly, 6 mg or 8 mg once every 2 weeks20 weeksn not reported2022
−9.1 kg
Total body weight change
Dose studied: 2.4 mg/wk24 weeksn = 1012026
0.3 to 0.38%
HbA1c reduction
Dose studied: 4 mg or 6 mg once weekly, 6 mg or 8 mg once every 2 weeks20 weeksn not reported2022
−1.6 to −0.4%
Estimated treatment difference
Dose studied: 2.5-40 mg once daily26 weeksn not reported2017
5 to 19%
Discontinuation due to adverse events
Dose studied: 4 mg once weekly, 6 mg once weekly, 6 mg once every 2 wk, or 8 mg once every 2 wk20 weeksn not reported2019
16.6%
discontinuation due to adverse events
Placebo: 8.2%
Dose studied: 2.4 mg once weeklyn = 17,6042023
| LipidsMetabolic and weightCompared as: difference from placebo, in % | No comparable result 2 randomized-trial results measure it in another way or another unit. | −7% Total cholesterol change at 13 weeks Dose studied: maximum 14 mg once dailyn = 9,6502026 |
|---|
| PharmacokineticsPharmacologyCompared as: value in the arm that got the peptide, in h·nmol/l | No comparable result 7 randomized-trial results measure it in another way or another unit. | 233 h·nmol/L AUC0-24h,sema,SS · 3 mg oral semaglutide Dose studied: 3 mg12 weeksn = 322024 |
|---|
| Gastrointestinal motilityGastrointestinalCompared as: difference from placebo, in % | No comparable result 2 randomized-trial results measure it in another way or another unit. | −31% Paracetamol AUC0-1h decrease · Shown as a change. The study reports a paracetamol auc0-1h decrease of this size. Dose studied: escalated to 14 mg once daily12 weeksn = 152021 |
|---|
| Gastrointestinal adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | No comparable result 10 randomized-trial results measure it in another way or another unit. | 5% Gastrointestinal disorders Placebo: 4.4% Dose studied: maximal dose 14 mg once dailyn = 9,6502025 |
|---|
No comparable result
10 randomized-trial results measure it in another way or another unit.
6.5%
primary end-point event rate
Placebo: 8%
Dose studied: 2.4 mg once weeklyn = 17,6042023
No comparable result
2 randomized-trial results measure it in another way or another unit.
−7%
Total cholesterol change at 13 weeks
Dose studied: maximum 14 mg once dailyn = 9,6502026
No comparable result
7 randomized-trial results measure it in another way or another unit.
233 h·nmol/L
AUC0-24h,sema,SS · 3 mg oral semaglutide
Dose studied: 3 mg12 weeksn = 322024
No comparable result
2 randomized-trial results measure it in another way or another unit.
−31%
Paracetamol AUC0-1h decrease · Shown as a change. The study reports a paracetamol auc0-1h decrease of this size.
Dose studied: escalated to 14 mg once daily12 weeksn = 152021
No comparable result
10 randomized-trial results measure it in another way or another unit.
5%
Gastrointestinal disorders
Placebo: 4.4%
Dose studied: maximal dose 14 mg once dailyn = 9,6502025